Johanna Schaub
Company: Pliant Therapeutics
Job title: Principal Scientist - Translational Sciences
Seminars:
Selectively Targeted TGF-β Activating Integrin, αvβ8 & αvβ8 in Solid Tumors to Increase Sensitivity to Checkpoint Inhibition Therapies 10:00 am
Avoiding systemic toxicity by selective tatrgeting of TGF-β activating integrins in the tumor microenvironment with an oral small molecule inhibitor Anti-tumor activity from blocking distinct integrin-regulated TGF-β pathways on T-cells, tumor and stromal cells Activity as both a single agent in combination with checkpoint inhibitors in multiple animal modelsRead more
day: Conference Day Two